Clinical Trial Update: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients [Phase 3]

View source ↗

Summary

LG Chem reports completion of a Phase 3, placebo-controlled trial of tigulixostat in patients with gout and hyperuricemia; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• Tigulixostat (tigulixostat)

Snippet

Sponsor: LG Chem | Conditions: Gout, Hyperuricemia | Phase 3 | Status: COMPLETED